Medivir Enrollment Completed in the MIV-711 Osteoarthritis Extension Study and Data Monitoring Committee Recommendation

Medivir AB (Nasdaq Stockholm: MVIR) today announced continued progress towards the completion of its phase IIa program for the treatment of osteoarthritis: The open label phase IIa extension study has completed enrollment The independent Data Monitoring Committee (DMC) has...